2-乙氧基-7-甲基萘 | 1134-45-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 2-乙氧基-7-甲基萘
• 英文名称: 2-Methyl-7-ethoxynaphthalin
• 英文别名: 2-Ethoxy-7-methylnaphthalene
• CAS: 1134-45-8
• 化学式: C₁₃H₁₄O
• 分子量: 186.254
• InChiKey: KSQURRKEYQVXHW-UHFFFAOYSA-N

物化性质

• 熔点：
  70-72 °C
• 沸点：
  303.4±11.0 °C(Predicted)
• 密度：
  1.032±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• CYCLOPENTA[C]PYRROLE-2-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
  申请人：Abouabdellah Ahmed

  公开号：US20120095040A1

  公开（公告）日：2012-04-19

  The invention relates to compounds of the general formula (I) where: R 2 is a hydrogen or fluorine atom or a hydroxyl, cyano, trifluoromethyl, C 1-6 -alkyl, C 1-6 -alkoxy, or NR 8 R 9 group; m, n, o and p independently are a number from 0 to 3; A is a covalent bond, an oxygen atom, a C 1-6 -alkylene group or a —O—C 1-6 -alkylene group in which the end that is an oxygen atom is bonded to the R 1 group while the end that is an alkylene group is bonded to the carbon of the bicyclic compound; R 1 is an optionally substituted aryl or heteroaryl group; R 3 is a hydrogen or fluorine atom or a C 1-6 -alkyl or trifluoromethyl group; R 4 is an optionally substituted 5-membered heterocyclic compound; wherein the compounds can be in the state of a base or an acid addition salt. The invention can be used in therapeutics.

  该发明涉及一般式（I）的化合物，其中：R2是氢原子或氟原子或羟基、氰基、三氟甲基、C1-6-烷基、C1-6-烷氧基或NR8R9基团；m、n、o和p独立地是从0到3的数字；A是共价键、氧原子、C1-6-烷基烯基团或—O—C1-6-烷基烯基团，其中一个端是氧原子与R1基团结合，而另一个端是烷基烯基团与双环化合物的碳结合；R1是可选择取代的芳基或杂环芳基；R3是氢原子或氟原子或C1-6-烷基或三氟甲基基团；R4是可选择取代的5-成员杂环化合物；其中这些化合物可以处于碱性或酸性盐的状态。该发明可用于治疗学。
• 7-AZA-SPIRO[3.5]NONANE-7-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
  申请人：Abouabdellah Ahmed

  公开号：US20120129830A1

  公开（公告）日：2012-05-24

  The invention relates to compounds of the general formula (I) where: R 2 is a hydrogen or fluorine atom or a hydroxyl, cyano, trifluoromethyl, C 1-6 -alkyl, C 1-6 -alkoxy, or NR 8 R 9 group; m, n, o and p independently are a number from 0 to 3, provided that m+n≦7 and that o+p≦7; A is a covalent bond, an oxygen atom, a C 1-6 -alkylene group or a —O—C 1-6 -alkylene group in which the end that is an oxygen atom is bonded to the R 1 group and the end that is an alkylene group is bonded to the carbon of the bicyclic compound; R 1 is an optionally substituted aryl or heteroaryl group; R 3 is a hydrogen or fluorine atom or a C 1-6 -alkyl or trifluoromethyl group; R 4 is an optionally substituted 5-membered heterocyclic compounds; wherein the compounds can be in the state of a base or an acid addition salt. The invention can be used in therapeutics.

  该发明涉及一般式（I）的化合物，其中：R2为氢或氟原子，或羟基、氰基、三氟甲基、C1-6-烷基、C1-6-烷氧基或NR8R9基团；m、n、o和p独立地为0到3之间的数字，但要求m+n≦7且o+p≦7；A为共价键、氧原子、C1-6-烷基烯基团或—O—C1-6-烷基烯基团，其中以氧原子为端点的部分与R1基团结合，以烷基烯基团为端点的部分与双环化合物的碳结合；R1为可选择取代的芳基或杂环芳基；R3为氢或氟原子，或C1-6-烷基或三氟甲基基团；R4为可选择取代的5-成员杂环化合物；其中这些化合物可以处于碱性或酸性盐的状态。该发明可用于治疗学。
• DISUBSTITUTED PIPERIDINE DERIVATIVES AS BUTYRYLCHOLINESTERASE INHIBITORS FOR USE IN THE TREATMENT OF ALZHEIMER
  申请人：Univerza V Ljubljani

  公开号：US20180086707A1

  公开（公告）日：2018-03-29

  This invention relates to new inhibitors of butyrylcholinesterase with general formulas I and II, where substituents are described in patent description. Compounds can be in the form of pure enantiomers or as racemic mixtures, or in the form of pharmaceutically acceptable salts. The present invention relates to the use of these inhibitors for the treatment of Alzheimer's disease and other forms of dementia.
• US8394787B2
  申请人：——

  公开号：US8394787B2

  公开（公告）日：2013-03-12
• US8697883B2
  申请人：——

  公开号：US8697883B2

  公开（公告）日：2014-04-15